Scientists discover how mitochondria import antioxidants

Cells solve this problem by synthesizing antioxidants, compounds that neutralize free radicals. In a new study, Rockefeller scientists identify a key molecule that ferries glutathione, the body's major antioxidant, into the cell's mitochondria, where free radicals are produced en masse. The discovery, published in Nature, opens new possibilities for investigating oxidative stress and its damaging effects.

"With the potential transporter identified, we can now control the amount of glutathione that enters mitochondria and study oxidative stress specifically at its source," says Kivanç Birsoy, Chapman Perelman Assistant Professor at The Rockefeller University.

The shuttle into the mitochondria

To avoid oxidative stress, cells need to properly balance the levels of free radicals and antioxidants within their mitochondria, where energy production happens. Because glutathione is produced outside of mitochondria, in the cell's cytosol, the scientists wanted to know how it gets transported into these tiny powerhouses in the first place.

To shed light on this process, Birsoy's team monitored protein expression in cells in response to glutathione's levels. "We hypothesized that glutathione is shuttled by a transporter protein whose production is regulated by glutathione," Birsoy says. "So if we lower the levels of glutathione, the cell should compensate by upregulating the transporter protein."

The analysis pointed to SLC25A39, a protein in the mitochondrial membrane whose function was hitherto unknown. The researchers found that blocking SLC25A39 reduced glutathione inside the mitochondrion, without affecting its levels elsewhere in the cell. Other experiments showed that mice cannot survive without SLC25A39. In animals engineered to lack this protein, red blood cells quickly die by oxidative stress due to their failure to bring glutathione into mitochondria.

The identification of the transporter may lead to a better understanding of a variety of disease pathways linked to oxidative stress, including those involved in aging and neurodegeneration. "These conditions could potentially be treated or prevented by stimulating antioxidant transport into mitochondria," Birsoy says.

Moreover, the team is now exploring whether SLC25A39 might hold promise as a drug target for cancer, by helping to induce fatal oxidative stress in tumor cells. "In cancer, we would want to prevent antioxidants from getting into mitochondria, and the transporter protein may be our way to do that," Birsoy says.